This EMCDDA Best Practice Portal page refers to the current evidence on the effectiveness of the available harm reduction options for opioid injectors. It includes updated information on the effectiveness of opioid substitution treatment (OST) and needle and syringe programmes (NSP) on HIV and HCV related outcomes as well as on Naloxone to prevent overdose mortality. To view the full information please click here

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert